Hi, Today I will be analyzing the MIT article "A new immunotherapy approach could work for many types of cancer." This article explains the development of a new immunotherapy that blocks sugar-based immune checkpoints on cancer cells. This is highly effective due to the immune system's enhanced ability to attack tumors.
- The new therapy works by disabling the cell signal that cancer cells use to avoid being attacked.
- Unlike other inhibitors, this approach targets glycans, which are sugar molecules on tumor cell surfaces.
- Molecules called AbLecs combine lectins and antibodies that target tumors.
- Through the blocking of glycan and Siglec interactions, the therapy reactivates immune cells such as macrophages and natural killer cells.
-
Experiments illustrate that AbLecs significantly increased the immune destruction of cancer cells.
- With mice, the treatment reduced metastatic lung tumors more effectively than standard antibody therapy.
-
Different antibodies and lectins can be used instead to treat various cancer types.
- Right now, early commercialization has started with the biotech company Valora Therapeutics, and clinical trials soon.
Add comment
Comments